Precision BioSciences (DTIL) announced the activation of its first U.S. clinical trial site to evaluate PBGENE-HBV as part of the ELIMINATE-B Phase 1 clinical trial. The newly activated site at Massachusetts General Hospital in Boston, Massachusetts, is now actively recruiting patients.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences announces presentation at WMS on PBGENE-DMD
- Precision BioSciences announces in vivo gene editing program patent from USPTO
- Precision BioSciences Updates Executive Employment Agreements
- Precision BioSciences: Promising Clinical Milestones and Strategic Advancements Drive Buy Rating
- Precision BioSciences Reports Significant Quarterly Loss